Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

ObjectiveTo assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain.MethodsA 3-year budget impact analysis model was adapted to estimate the cost of introducing biosimilars...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (e1), p.e40-e47
Hauptverfasser:	Calleja, Miguel Angel, Albanell, Joan, Aranda, Enrique, García-Foncillas, Jesús, Feliu, Anna, Rivera, Fernando, Oyagüez, Itziar, Salinas-Ortega, Laura, Soto Alvarez, Javier
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult antineoplastic agents Bevacizumab - therapeutic use Biological products Biosimilar Pharmaceuticals - therapeutic use Discount rates economics health care economics and organizations Humans medical oncology Neoplasms - drug therapy Neoplasms - epidemiology Original Research pharmaceutical Pharmaceutical Preparations Pharmaceuticals public health Spain - epidemiology Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!